PMID- 34434575
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220426
IS  - 1507-1367 (Print)
IS  - 2083-4640 (Electronic)
IS  - 1507-1367 (Linking)
VI  - 26
IP  - 4
DP  - 2021
TI  - Dosimetric study of Hounsfield number correction effect in areas influenced by 
      contrast product in lungs case.
PG  - 590-597
LID - 10.5603/RPOR.a2021.0083 [doi]
AB  - BACKGROUND: The aim of the study was dosimetric effect quantification of 
      exclusive computed tomography (CT) use with an intravenous (IV) contrast agent 
      (CA ), on dose distribution of 3D-CRT treatment plans for lung cancer. 
      Furthermore, dosimetric advantage investigation of manually contrast-enhanced 
      region overriding, especially the heart. MATERIALS AND METHODS: Ten patients with 
      lung cancer were considered. For each patient two planning CT sets were initially 
      taken with and without CA. Treatment planning were optimized based on CT scans 
      without CA. All plans were copied and recomputed on scans with CA. In addition, 
      scans with IV contrast were copied and density correction was performed for heart 
      contrast enhanced. Same plans were copied and replaced to undo dose calculation 
      errors that may be caused by CA. Eventually, dosimetric evaluations based on dose 
      volume histograms (DVHs) of planning target volumes (PTV) and organs at-risk were 
      studied and analyzed using the Wilcoxon's signed rank test. RESULTS: There is no 
      statistically significant difference in dose calculation for the PTV maximum, 
      mean, minimum doses, spinal cord maximum doses and lung volumes that received 20 
      and 30 Gy, between planes calculated with and without contrast scans (p > 0.05) 
      and also for contrast scan, with manual regions overriding. CONCLUSIONS: Dose 
      difference caused by the contrast agent is negligible and not significant. 
      Therefore, there is no justification to perform two scans, and using an IV 
      contrast enhanced scan for dose calculation is sufficient.
CI  - (c) 2021 Greater Poland Cancer Centre.
FAU - Oulhouq, Yassine
AU  - Oulhouq Y
AUID- ORCID: 0000-0001-6213-7588
AD  - LPMR, Faculty of Sciences, University Mohamed 1, Oujda, Morocco.
AD  - HASSAN II Oncology Center, University Hospital Mohammed VI, Oujda, Morocco.
FAU - Bakari, Dikra
AU  - Bakari D
AD  - National School of Applied Sciences, University Mohamed 1, Oujda, Morocco.
FAU - Krim, Deae-Eddine
AU  - Krim DE
AD  - LPMR, Faculty of Sciences, University Mohamed 1, Oujda, Morocco.
FAU - Zerfaoui, Mustapha
AU  - Zerfaoui M
AD  - LPMR, Faculty of Sciences, University Mohamed 1, Oujda, Morocco.
FAU - Rrhioua, Abdeslem
AU  - Rrhioua A
AD  - LPMR, Faculty of Sciences, University Mohamed 1, Oujda, Morocco.
FAU - Berhili, Soufiane
AU  - Berhili S
AD  - HASSAN II Oncology Center, University Hospital Mohammed VI, Oujda, Morocco.
FAU - Mezouar, Loubna
AU  - Mezouar L
AD  - HASSAN II Oncology Center, University Hospital Mohammed VI, Oujda, Morocco.
LA  - eng
PT  - Journal Article
DEP - 20210812
PL  - Poland
TA  - Rep Pract Oncol Radiother
JT  - Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer 
      Center in Poznan and Polish Society of Radiation Oncology
JID - 100885761
PMC - PMC8382071
OTO - NOTNLM
OT  - 3D-CRT
OT  - PTV
OT  - contrast agent
OT  - dose calculation
OT  - lung cancer
OT  - tomography
COIS- Conflict of interests The authors declare that they have no known competing 
      financial interests or personal relationships that could have appeared to 
      influence the work reported in this paper.
EDAT- 2021/08/27 06:00
MHDA- 2021/08/27 06:01
PMCR- 2021/08/12
CRDT- 2021/08/26 06:14
PHST- 2020/09/22 00:00 [received]
PHST- 2021/02/27 00:00 [accepted]
PHST- 2021/08/26 06:14 [entrez]
PHST- 2021/08/27 06:00 [pubmed]
PHST- 2021/08/27 06:01 [medline]
PHST- 2021/08/12 00:00 [pmc-release]
AID - rpor-26-4-590 [pii]
AID - 10.5603/RPOR.a2021.0083 [doi]
PST - epublish
SO  - Rep Pract Oncol Radiother. 2021 Aug 12;26(4):590-597. doi: 
      10.5603/RPOR.a2021.0083. eCollection 2021.